Klin Farmakol Farm. 2013;27(3-4):136-138

Using ertapenem in treating gynaecological and urological infections

Renáta Čermáková
Klinická mikrobiologie a ATB centrum ÚLBLD, Všeobecná fakultní nemocnice, Praha

The author reports the cases of four patients diagnosed with infections caused by bacterial strains producing extended-spectrum beta-

-lactamases (ESBL) and successfully treated with ertapenem, an antibiotic from the class of carbapenems. This alternate broad-spectrum

antibiotic is characterized by stability against the effects of most of the beta-lactamases. The mechanism of its effect can be described as

an inhibition of bacterial cell wall synthesis by connection to penicillin-binding proteins (PBP) followed by preventing transpeptidation

of peptidoglycan, it is bactericidal (5, 7).

Keywords: ertapenem, carbapenems, extended-spectrum beta-lactamases, infections

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermáková R. Using ertapenem in treating gynaecological and urological infections. Klin Farmakol Farm. 2013;27(3-4):136-138.
Download citation

References

  1. Beneš J. Ertapenem a jeho postavení mezi ostatními karbapenemy. Klin Farmakol Farm 2011; 25(3): 144-149.
  2. Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double - blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology, 2002; 60: 16-22. Go to original source... Go to PubMed...
  3. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-344. Go to original source... Go to PubMed...
  4. Roy S, Higareda I, Angel-Muller E, et al. Ertapenem once a day versus piperacilin-tazobactam every 6 hours for treatment of acut pelvic infections: a prospective, multicenter, randomized, double - blind study. Infect Dis Obstet Gynecol 2003; 11: 27-37. Go to original source... Go to PubMed...
  5. Suchopár J, Šťastná Koblihová H. Karbapenemy: přehled a porovnání základních údajů. Remedia 2008; 18: 247-251.
  6. Tomera KM, Burdman EA, Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double - blind multicenter study. Antimicrob Agents Chemother 2002; 46: 2895-2900. Go to original source... Go to PubMed...
  7. www.emea.europa.eu




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.